Oxidative stress in multi-port and single-port cholecystectomy

J Surg Res. 2015 Mar;194(1):101-6. doi: 10.1016/j.jss.2014.09.020. Epub 2014 Sep 28.

Abstract

Background: This study was designed to analyze and compare plasma levels of 8-isoprostane (8-epiPGF2α), a biomarker of lipid peroxidation, and uric acid (UA), a marker of the antioxidant status, in standard laparoscopic (LC) and laparoendoscopic single-site cholecystectomy (LSSC).

Materials and methods: Forty patients with noncomplicated cholelithiasis were randomized to undergo either LSSC (n = 20) or LC (n = 20). The patients had body mass index <30, American Society of Anesthesiologists score I or II, and no previous upper gastrointestinal surgery. Blood samples were taken preoperatively and 6 h and 24 h postoperatively. Levels of 8-epiPGF2α were determined using enzyme-linked immunosorbent assay, whereas levels of UA were calculated using automated analyzer.

Results: No significant differences were observed in operative data among the groups. Levels of 8-epiPGF2α were significantly higher in LSSC compared with LC at 6 h (P = 0.003) and 24 h (P < 0.001). 8-epiPGF2α levels showed significant changes over time in LC (LSSC: P = 0.720, LC: P < 0.001). UA levels were significantly higher in LC compared with LSSC, 24 h postoperatively (P = 0.021). No significant changes over time in the UA levels in both groups (LSSC: P = 0.056, LC: P = 0.205).

Conclusions: LSSC is associated with increased oxidative stress compared with LC. Further studies are needed to confirm these results.

Trial registration: ClinicalTrials.gov NCT01211743.

Keywords: 8-Isoprostane; Laparoendoscopic single-site cholecystectomy; Oxidative stress; Standard laparoscopic cholecystectomy; Uric acid.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Cholecystectomy, Laparoscopic / methods*
  • Dinoprost / analogs & derivatives
  • Dinoprost / blood
  • Female
  • Humans
  • Lipid Peroxidation
  • Male
  • Middle Aged
  • Oxidative Stress*
  • Uric Acid / blood

Substances

  • Uric Acid
  • 8-epi-prostaglandin F2alpha
  • Dinoprost

Associated data

  • ClinicalTrials.gov/NCT01211743